Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Free Cash Flow (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Free Cash Flow for 13 consecutive years, with -$6.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 24.89% to -$6.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $243.5 million, a 2359.98% increase, with the full-year FY2024 number at -$11.9 million, up 59.75% from a year prior.
  • Free Cash Flow was -$6.5 million for Q3 2025 at Theravance Biopharma, down from $208.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $208.1 million in Q2 2025 to a low of -$71.6 million in Q1 2021.
  • A 5-year average of $11.2 million and a median of -$5.2 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: decreased 27.79% in 2021, then skyrocketed 4774.77% in 2025.
  • Theravance Biopharma's Free Cash Flow stood at -$71.6 million in 2021, then skyrocketed by 176.29% to $54.6 million in 2022, then plummeted by 122.25% to -$12.2 million in 2023, then skyrocketed by 91.02% to -$1.1 million in 2024, then crashed by 495.97% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Free Cash Flow are -$6.5 million (Q3 2025), $208.1 million (Q2 2025), and $43.0 million (Q1 2025).